Topics
Low-grade gliomas | Treatment | Clinical trials | Temozolomide
Home > Publications > Topics > Low-grade gliomas > Treatment > Clinical trials > Temozolomide
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T,
Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E,
Philips C, Kros JM, Bady P, Wick W, Enting R, Reni M, Thiessen B,
Dhermain F, Bromberg JE, Jacob J, Reijneveld JC, Chinot O,
Gijtenbeek JMM, Rossiter JP, Balana C, Azevedo ALS, Clement PM,
Berghoff A, Tzuk-Shina T, Weller M, Nordal RA, Rees J, Lacombe DA,
Mason WP, Stupp R.
Temozolomide Versus
Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature
Results of a Randomized Phase III Trial (EORTC
22033-26033/NCIC-CTG/TROG/MRC-CTU).
J
Clin Oncol. 2026 Jul 2:JCO2502735. doi:
10.1200/JCO-25-02735. PMID:
42391581. Trial
registration ID: EORTC 22033-26033˰
ˍ
Marciscano AE, Shih HA.
Biology Over
Monotherapy: Mature Results From European Organisation For
Research and Treatment of Cancer 22033-26033 Reaffirm Molecular
Stratification, Not Treatment Sequence, Defines Prognosis in
Low-Grade Glioma.
J
Clin Oncol. 2026 Jul 2:JCO2600771. doi:
10.1200/JCO-26-00771. PMID:
42391595. ˍ